Bear Robotics Bets on Elevator Interoperability With a Strategic Investment in M2MTech
19.4.2023 15:57:00 EEST | Business Wire | Press release
Bear Robotics, a Silicon Valley-based innovator of indoor service robots, is continuing its advancements in the robotics and artificial intelligence space. The tech pioneers just announced a strategic investment to fund its Korea-based partner, M2MTech, which specializes in IoT convergence for smart remote and predictive systems with elevators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005038/en/
Servi Lift provides a reliable delivery experience with its elevator integration, making deliveries in multi-story buildings a breeze. (Photo: Business Wire)
This investment comes as Bear Robotics now extends their world-renowned Servi robot line with a fully integrated elevator delivery robot, Servi Lift, which is capable of completing last-mile deliveries inside of multi-story buildings such as hotels, senior living communities, ghost kitchens, hospitals, corporate campuses, and other high-rise commercial and residential real estate properties. "We believe this investment will truly maximize facility efficiencies and minimize user inconvenience,” commented John Ha, co-founder and Chief Executive Officer of Bear Robotics. “The ELSA convergence platform developed by M2MTech provides strong security, interoperability, and connectivity advantages that will set the stage for us to scale our last-mile mobility solutions.”
In engineering Servi Lift, Bear Robotics sought interoperability as its absolute competitive advantage to be applied with major players in the smart elevator market such as OTIS, TKE, Mitsubishi, KONE, Hyundai and Schindler. With the expansion of urbanization, Bear Robotics is bullish on the “smart city” shift to robot-friendly buildings, enhanced access security, and the penetration of smart elevators in smart buildings with strong linkages between systems. “With the global IoT elevator market forecasted to grow to $64 billion by 2030, it was imperative for us to invest into our close partnership with M2MTech that our engineering teams have built over the last couple of years, and to realize the synergies we believe will advance our last-mile aspirations,” commented Juan Higueros, co-founder and Chief Operating Officer of Bear Robotics. “We are confident that this collaborative approach will generate more efficient operations for many of our existing customers and open a broad array of new opportunities that will place Bear Robotics in a position to be the world’s leading multi-story robot delivery solutions provider.”
100 trials of Servi Lift are reserved for 2023. Broader rollouts are lined up across the world in 2024.
About Bear Robotics
Founded in 2017, Bear Robotics manufactures self-driving indoor robots to assist employees on daily tasks that can ease their workload. The Company’s flagship Servi robots have been deployed in hospitality, healthcare, retail, and real estate venues in North America, Europe, and Asia. For additional information, please visit www.bearrobotics.ai.
About M2MTech
Founded in 2014, M2MTech has developed an open and interoperable platform named ELSA (Elevator Smart Advisor, Elevator Smart Remote Management, Smart Predictive Maintenance System). For additional information, please visit https://m2mtech.co.kr/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005038/en/
Contact information
Alison Suzuki
Phone: 1-844-SAY-BEAR
Email:
press@bearrobotics.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 18:00:00 EEST | Press release
Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment in cardiovascular health and its mission to care for every heartbeat. The 15-abstract showcase provides a comprehensive look at the role of bempedoic acid in lipid management. This includes post-hoc analyses in collaboration with Esperion Therapeutics from the Phase 3 CLEAR Outcomes trial exploring its impact on stroke and venous thromboembolism (VTE) incidence.5,6 There are also real-world findings from the MILOS registry, including a dedicated sub-analysis investigating the effectiveness of bempedoic acid across various background therapies.1,2,3,4 Results reinforce consistent effectiveness and safety profile of bempedoic acid across various EU countries and regardless of patients’ existing treatm
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom